Synthetic Biologics Inc (SYN) 2.31 $SYN Our 2 Healthcare

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Synthetic Biologics Inc (SYN) 2.31 $SYN

Our 2 Healthcare Picks For April
Lowenthal Capital Partners - at Seeking Alpha - Tue Apr 14, 5:25AM CDT

SYN: 2.31 (-0.07), GSK: 46.57 (-0.67)

Synthetic Biology - Global Strategic Business Report 2015-2020
M2 - Wed Apr 08, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3bgw8/synthetic_biology) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Product Segments: Enabled Products, and Others. The report also analyzes the market by the following Application Areas: Energy and Chemicals, Biotechnology and Pharmaceuticals, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 51 companies including many key and niche players such as: Players Focused on Synthetic Biology Applications - Amyris, Inc. (US) - BP PLC. (UK) - Chromatin Inc. (US) - Evolva SA (Switzerland) - Gevo, Inc. (US) - Joule Unlimited, Inc. (US) - Metabolix (US) - MorphoSys AG (Germany) - Sapphire Energy, Inc. (US) - Solazyme, Inc. (US) - Synthetic Biologics, Inc. (US) - Synthetic Genomics, Inc. (US) Players Focused on Gene Synthesis and Tools - 454 Life Sciences (US) - Agilent Technologies Inc. (US) - ATG Biosynthetics GmbH (Germany) - DNA2.0 (US) - Epoch Life Science, Inc. (US) - Gen9, Inc. (US) - GenScript USA, Inc. (US) - Gingko Bioworks, Inc. (US) - Intrexon Corporation (US) - LC Sciences LLC (US) - Life Technologies Corp. (US) - OPXBIO, Inc. (US) - OriGene Technologies, Inc. (US) - Sangamo BioSciences, Inc. (US) - Verdezyne, Inc. (US Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS, DRIVERS, AND ISSUES 4. KEY RESEARCH FINDINGS ON SYNTHETIC BIOLOGY 5. SYNTHETIC BIOLOGY - AN OVERVIEW 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 51 (including Divisions/Subsidiaries (52) - The United States (41) - Canada (1) - Europe (8) - France (1) - Germany (3) - The United Kingdom (1) - Spain (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/t3...ic_biology
SYN: 2.31 (-0.07), AMRS: 2.61 (unch), A: 42.71 (-0.18), SGMO: 14.37 (-0.03), XON: 44.53 (+0.36), GEVO: 2.79 (+0.78), SZYM: 3.71 (-0.06)

Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015
PR Newswire - Wed Apr 01, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that clinical data supporting the development of SYN-004, the Company's candidate therapy designed to degrade certain beta-lactam intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections, has been selected for presentation during the 115th General Meeting of the American Society of Microbiology (ASM2015) in New Orleans, LA on May 30-June 1.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 8:11AM CDT

BDSI: 9.26 (+0.12), CRMD: 8.86 (-0.28), NCFT: 25.87 (+0.17), LEJU: 9.16 (+0.65), CTRX: 59.46 (-0.11), ZIOP: 10.88 (+0.03), ADXS: 22.18 (+0.10), CNAT: 6.31 (-0.15), XON: 44.53 (+0.36), BBEP: 6.40 (-0.10), ADMP: 4.66 (-0.01), CLDN: 13.59 (-2.77), ASPX: 100.79 (+0.09), HPTX: 45.96 (-0.18), GENE: 4.88 (-0.05), SYN: 2.31 (-0.07), ICEL: 16.47 (-0.02), HZNP: 30.96 (+0.10), OHRP: 2.72 (+0.08), SFUN: 7.82 (+0.64), CNET: 1.56 (unch)

Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile
PR Newswire - Mon Mar 30, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). C. difficile is the leading type of hospital acquired infection and is frequently associated with intravenous (IV) antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection management, and include commonly used penicillin and cephalosporin antibiotics, such as ceftriaxone.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)

Cough Therapeutics Pipeline Review 2015 Featuring 34 Companies
M2 - Wed Mar 25, 12:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpt4xp/cough_pipeline) has announced the addition of the "Cough - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Afferent Pharmaceuticals, Inc. - Ahn-Gook Pharmaceutical Co., Ltd. - Alitair Pharmaceuticals, Inc. - Ario Pharma Ltd - AUS Bio Limited - Beijing Minhai Biotechnology Co., Ltd - Beijing Tiantan Biological Products Co., Ltd. - Bharat Biotech International Limited - Biological E. Limited - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - Green Cross Corporation - Hanmi Pharmaceuticals, Co. Ltd. - Hydra Biosciences, Inc. - Hyundai Pharmaceutical Co., Ltd. - Indian Immunologicals Limited - LG Life Sciences, Ltd. - NanoBio Corporation - Neos Therapeutics, Inc. - Novartis AG - Orbis Biosciences, Inc. - Panacea Biotec Limited - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/qp...h_pipeline
SYN: 2.31 (-0.07), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10), NVS: 103.45 (-0.62)

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Thu Mar 19, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)

Synthetic Biologics' (SYN) CEO Jeff Riley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 11:15AM CDT

SYN: 2.31 (-0.07)

Stocks Coverage on the Health Care Sector - AstraZeneca, Novartis, Raptor Pharma, Synthetic Biologics, and BioDelivery Sciences Intl.
PR Newswire - Mon Mar 16, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BDSI: 9.26 (+0.12), SYN: 2.31 (-0.07), RPTP: 10.56 (-0.17), AZN: 73.35 (+0.65), NVS: 103.45 (-0.62)

Synthetic Biologics FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT

SYN: 2.31 (-0.07)

Synthetic Biologics reports FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 6:02AM CDT

SYN: 2.31 (-0.07)

Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights
PR Newswire - Mon Mar 16, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the year ended December 31, 2014, and provided an operational update.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)

Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.31 (-0.07), ZIOP: 10.88 (+0.03), UNIS: 3.79 (-0.12), FCSC: 4.01 (+0.01), XON: 44.53 (+0.36), MNKD: 4.90 (-0.09)

Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.12), VRTX: 132.85 (+0.65), CERU: 5.99 (-0.20), FOMX: 10.94 (-0.02), ONTX: 2.48 (-0.05), PFNX: 15.12 (+0.42), OMER: 24.41 (-0.15), PGNX: 6.33 (-0.12), SYN: 2.31 (-0.07), VCYT: 8.15 (+0.05), STEM: 0.82 (-0.06), APRI: 1.77 (-0.02), KPTI: 32.24 (-0.60)

Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015
PR Newswire - Wed Mar 11, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company's candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:45AM CDT

HTBX: 7.71 (-0.64), CTRV: 3.13 (-0.07), AKRX: 53.70 (-1.69), BRSS: 15.30 (+0.25), CASI: 1.52 (+0.03), JOB: 0.84 (+0.04), LL: 33.86 (+0.50), MIND: 4.97 (+0.05), BBNK: 27.26 (+0.36), WPRT: 4.39 (+0.01), URBN: 42.17 (+0.03), OCC: 4.18 (-0.04), SYN: 2.31 (-0.07), IDT: 17.66 (unch), GERN: 4.20 (-0.04), TITN: 14.25 (+0.15), IMPV: 47.68 (-0.88), NNBR: 24.82 (+0.05), REPH: 10.71 (-0.78), VPCO: 0.80 (unch)

Synthetic Biologics to Report Year End 2014 Financial Results
PR Newswire - Mon Mar 09, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Company will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)

Synthetic Biologics to Present at the 27th Annual ROTH Conference
PR Newswire - Tue Mar 03, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
SYN: 2.31 (-0.07), XON: 44.53 (+0.36)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 32

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 89

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 73

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 40

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 129

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 18

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 192

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 62

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 74

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading

Top 5 Most Recently Viewed Articles

Legit Security Named as a Top Performer in Application Security

Updated Category News Views 210

Legit Security Recognized as a Leader in Application Security Legit Security, a leader in AI-native Application Security Posture Management (ASPM), has recently been acknowledged as a prominent player in the IDC MarketScape for ASPM. This achievement reflects the company's commitment to securing AI-powered application development processes. The IDC MarketScape report...

Continue Reading
Active Dental Transforms Patient Experience with New Website

Updated Category News Views 140

Active Dental Enhances Patient Accessibility with Unified Website Active Dental, a reputable family and general dentistry practice in the Dallas-Fort Worth metroplex, has launched a newly redesigned website that seamlessly integrates all five of its practice locations into a single, user-friendly digital platform. This significant upgrade aims to make appointment...

Continue Reading
Stork Club's Innovative Approach to Postpartum Depression Support

Updated Category News Views 229

Stork Club Innovates Reproductive Health Care Stork Club has recently launched an unprecedented initiative aimed at addressing postpartum depression (PPD) among working mothers. This pioneering program offers a seamless blend of digital diagnostics and therapy, leading to significant improvements in mental health outcomes. With up to 20% immediate relief from PPD symptoms...

Continue Reading
Investors Eye Class Action Against Fortrea Holdings, Inc.

Updated Category News Views 114

Understanding the Fortrea Holdings, Inc. Class Action Fortrea Holdings, Inc. (NASDAQ: FTRE) has gained attention due to rising investor concerns regarding its recent financial disclosures. Investors who have experienced losses over $100,000 are now presented with an opportunity to potentially lead a securities fraud lawsuit against the company. This lawsuit highlights...

Continue Reading
Alpha Tau Medical Plans Engagements at Key Healthcare Events

Updated Category News Views 91

Upcoming Participation in Major Healthcare Conferences Alpha Tau Medical Ltd., a leading developer of innovative cancer therapies, is gearing up for an exciting presence at significant healthcare conferences. The involvement of the Chief Financial Officer, Raphi Levy, at these events marks a pivotal opportunity for the company to showcase its groundbreaking...

Continue Reading